vimarsana.com

Latest Breaking News On - Hr positive breast cancer - Page 1 : vimarsana.com

The Role of Elacestrant in Breast Cancer

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

Erical mayerBreast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsEndocrine therapiesEmerald studyEmerald trialPi3k mutations

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

Breast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsOral serdsSerena 2Adverse effects

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Breast cancerAdvanced breastHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsBiomarker testingEsr1 testingPada 1Circulating tumor dnaAromatase inhibitorPatient monitoring

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

Kevin kalinskyBreast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsEmerald studyEmerald trial

Testing for ESR1 Mutations in Breast Cancer

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Erical mayerKevin kalinskyBreast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsBiomarker testingEsr1 testingAsco recommendationsCirculating tumor dna

vimarsana © 2020. All Rights Reserved.